@article{3d5933ecb59647b2aa0f23c77f99112d,
title = "Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma",
abstract = "Elevated intraocular pressure (IOP) is a major, and currently the only, modifiable risk factor that has been shown to reduce the risk of glaucoma onset and progression. Diurnal measurements of IOP, usually during office hours, are commonly used for the assessment of IOP variation and the relative success of medical, laser, or surgical IOP-lowering interventions. Such measurements, however, fail to capture variation in IOP over the day/night cycle, which may be influenced by factors such as body position. We examine current evidence in the field of IOP measurement and control—with a focus on 24-hour (circadian) study design and measurement techniques and the 24-hour efficacy of current treatments—in patients with glaucoma and ocular hypertension. We then provide our recommendations for the design of future studies of circadian IOP with the aim of improving the assessment, management, and treatment of patients with glaucoma and ocular hypertension.",
keywords = "24 hour, circadian, glaucoma, intraocular pressure, measurement, nocturnal, ocular hypertension",
author = "Kaweh Mansouri and Tanna, {Angelo P.} and {De Moraes}, {Carlos Gustavo} and Camp, {Andrew S.} and Weinreb, {Robert N.}",
note = "Funding Information: K. Mansouri has received consultant/advisor fees from Implandata, Santen, and SENSIMED; has received grant/research support from Alcon, Allergan, Optovue, and Topcon. A.P. Tanna has received consultant/advisor fees from Alcon, Bausch and Lomb, Par Pharmaceuticals, Sandoz, and Watson laboratories, Inc.; has acted as consultant/advisor to Galimedix and Novartis. C.G. De Moraes has received grant/research support from Carl Zeiss Meditec, Inc., Heidelberg Engineering GmbH, the National Eye Institute National Institutes of Health, and Topcon, Inc. A.S. Camp has nothing to disclose. R.N. Weinreb has received grant/research support from Bausch and Lomb, Centervue, Genentech, Heidelberg Engineering GmbH, Konan, Meditec-Zeiss, the National Eye Institute, and Optovue; has acted as consultant/advisor to Aeries Pharmaceuticals, Allergan, Bausch and Lomb, Eyenovia, Implandata, SENSIMED, and Novartis; and has patents/has received royalties for intellectual property through the University of California San Diego from Meditec-Zeiss and Toromedes.The authors acknowledge Jessica Donaldson-Jones of Fishawack Communications Ltd, Abingdon, UK, who provided manuscript drafting, editorial, and medical writing support, funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Supported in part by an unrestricted grant to Dr. Weinreb by Research to Prevent Blindness (New York, NY). Funding Information: K. Mansouri has received consultant/advisor fees from Implandata, Santen, and SENSIMED; has received grant/research support from Alcon , Allergan , Optovue , and Topcon. A.P. Tanna has received consultant/advisor fees from Alcon, Bausch and Lomb, Par Pharmaceuticals, Sandoz, and Watson laboratories, Inc.; has acted as consultant/advisor to Galimedix and Novartis. C.G. De Moraes has received grant/research support from Carl Zeiss Meditec, Inc. , Heidelberg Engineering GmbH , the National Eye Institute National Institutes of Health , and Topcon, Inc . A.S. Camp has nothing to disclose. R.N. Weinreb has received grant/research support from Bausch and Lomb , Centervue , Genentech , Heidelberg Engineering GmbH , Konan , Meditec-Zeiss , the National Eye Institute , and Optovue ; has acted as consultant/advisor to Aeries Pharmaceuticals, Allergan, Bausch and Lomb, Eyenovia, Implandata, SENSIMED, and Unity; and has patents/has received royalties for intellectual property through the University of California San Diego from Meditec-Zeiss and Toromedes. Funding Information: The authors acknowledge Jessica Donaldson-Jones of Fishawack Communications Ltd, Abingdon, UK, who provided manuscript drafting, editorial, and medical writing support, funded by Novartis Pharmaceuticals Corporation , East Hanover, NJ, USA. Supported in part by an unrestricted grant to Dr. Weinreb by Research to Prevent Blindness (New York, NY). A Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
month = mar,
day = "1",
doi = "10.1016/j.survophthal.2019.09.004",
language = "English (US)",
volume = "65",
pages = "171--186",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "2",
}